Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in the development and commercialization of controlled release combination therapeutics to treat healthcare problems, primarily in the areas of infectious diseases and central nervous system disorders. It also develops novel extended release and combination products for symptomatic treatment of dementia. The company was incorporated in 2000 and is headquartered in Emeryville, California with operations in India, the United States, and Singapore.

NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Adamas Pharmaceuticals, Inc. (ADMS) Settlement Fund Before Deadline

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

$4,650,000 Recovery from Adamas Pharmaceuticals, Inc. (ADMS). L&K, LLP Reminds Shareholders to File a Claim Before Deadline

NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Levi & Korsinsky, LLP Announces $4,650,000 Recovery for Adamas Pharmaceuticals, Inc. (ADMS). File Your Claim Before Deadline

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery

NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement

OAKLAND, Calif. , May 13, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP announce that the United States District Court for the Northern District of California has approved the following announcement of a proposed class action settlement that would benefit purchasers of the publicly traded common stock of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS): SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION, CERTIFICATION OF SETTLEMENT CLASS, AND PROPOSED SETTLEMENT; (II) SETTLEMENT FAIRNESS HEARING; AND (III) MOTION FOR AN AWARD OF ATTORNEYS' FEES AND REIMBURSEMENT OF LITIGATION EXPENSES TO: All persons and entities who, during the period between August 8, 2017 and March 4, 2019, inclusive, purchased or otherwise acquired the publicly traded common stock of Adamas Pharmaceuticals, Inc. ("Adamas"), and were damaged thereby (the "Settlement Class"): 1 Please read this notice carefully, your rights will be affected by a class action lawsuit pending in this court.

Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMS

Atlantic Capital Bancshares

Dawson Geophysical

PAE Inc

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Dawson Geophysical Company (NASDAQ: DWSN) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dawson Geophysical Company (NASDAQ: DWSN) in connection with the proposed acquisition of DWSN by a subsidiary of Wilks Brothers, LLC.

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, ADMS, and ACBI Shareholders About Its Ongoing Investigations

Echo Global Logistics

Oasis Midstream Partners

NEW YORK, Nov. 2, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com   Oasis Midstream Partners LP (NASDAQ: OMP)  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oasis Midstream Partners LP (NASDAQ: OMP) in connection with the proposed merger of the company with Crestwood Equity Partners LP ("Crestwood").

SHAREHOLDER ALERT: WeissLaw LLP Reminds OMP, ADMS, ACBI and ECHO Shareholders About Its Ongoing Investigations

NEW ORLEANS, Nov. 2, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

ADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know

Flexion Therapeutics

FTS Int.

Umpqua Holdings

NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: FTS International, Inc. (NYSE: FTSI)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ProFrac Holdings, LLC for $26.52 per share in cash. If you are an FTS International shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm

Aspen Technology Inc

Eagle Bancorp Montana

NEW YORK, Oct. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) in connection with the proposed acquisition of the company by Supernus Pharmaceuticals, Inc.  Under the terms of the agreement, ADMS shareholders will receive $8.10 per share in cash, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of ADMS's lead product, GOCOVRI, for each share of ADMS stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

Supernus Pharmaceuticals

Adamas looks like a good fit for Supernus.

Why Supernus' Acquisition of Adamas Is a Smart Move

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Adamas Pharmaceuticals, Inc. ("ADMS" or the "Company") (ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, ADMS shareholders will receive $8.10 plus two contingent value rights collective worth $1.00 in cash per share they own. The investigation focuses on whether Adamas Pharmaceuticals, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) in connection with the proposed acquisition of the Company by Supernus Pharmaceuticals, Inc. ("Supernus") (NASDAQ: SUPN), via a tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $8.10 per share in cash payable at closing, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of the Company's lead product, GOCOVRI, for each share of Adamas common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Adamas Pharmaceuticals, Inc.

New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) ("Adamas" or the "Company") stock prior to October 11, 2021. To view an enhanced version of this graphic, please visit:

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Adamas Pharmaceuticals, Inc. with Supernus Pharmaceuticals, Inc.

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus. Click here to learn how to join the action: https://www.ademilaw.com/case/adamas-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus

ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News appeared first on InvestorPlace.

ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash is fair to Adamas shareholders. Halper Sadeh encourages Adamas shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halpe

Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADMS

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal consideration includes $8.10 per share in cash ($400 million) and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash.

Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights

The stock price of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) increased by over 70% pre-market today. This is why it happened.

ADMS Stock: Why It Substantially Increased Today

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of

Adamas Announces New Employment Inducement Grants

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Therapeutics category. This year's UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories

Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FD

News for Adamas Pharmaceuticals Stock (ADMS)